Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 479,400 shares, a decline of 52.0% from the February 13th total of 998,100 shares. Based on an average trading volume of 3,170,000 shares, the short-interest ratio is currently 0.2 days. Currently, 3.4% of the company’s shares are short sold.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Aethlon Medical in a research note on Wednesday. They issued a “sell” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Aethlon Medical in a research note on Monday, March 10th.

Aethlon Medical Stock Performance

Aethlon Medical stock opened at $0.37 on Friday. Aethlon Medical has a 1 year low of $0.24 and a 1 year high of $1.85. The company’s 50 day simple moving average is $0.62 and its 200-day simple moving average is $0.50. The company has a market capitalization of $5.40 million, a price-to-earnings ratio of -0.24 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.09. Equities analysts expect that Aethlon Medical will post -0.73 earnings per share for the current year.

Institutional Investors Weigh In On Aethlon Medical

Large investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC purchased a new stake in Aethlon Medical during the 4th quarter worth approximately $25,000. Allegiance Financial Group Advisory Services LLC purchased a new stake in shares of Aethlon Medical in the 4th quarter valued at approximately $26,000. Sassicaia Capital Advisers LLC purchased a new stake in shares of Aethlon Medical in the 4th quarter valued at approximately $31,000. Virtu Financial LLC purchased a new stake in shares of Aethlon Medical in the 4th quarter valued at approximately $81,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Aethlon Medical in the 4th quarter valued at approximately $186,000. 1.99% of the stock is owned by hedge funds and other institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.